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ABSTRACT 
One of the central components in regulating cell growth and cell cycle progression is the 
mammalian target of Rapamycin (mTOR) complex.  The mTOR complex consists of two distinct 
forms, mTORC1 and mTORC2.  As aberrant mTOR complex activity is a major causative factor 
of many diseases including Polycystic Kidney Diseases (PKD), mTOR has become a major 
therapeutic target in the last decade.  Rapamycin was the first macrolide drug known to inhibit 
mTOR activity, specifically inhibiting mTORC1.  Recently, small-molecule-inhibitors such as 
Torin2 have been designed to directly bind the catalytic domain of mTOR in order to inhibit both 
mTORC1 and mTORC2.  Using Rapamycin to block mTORC1, proximal tubular growth of 
Xenopus laevis can be partially abrogated.  Here, we investigate whether Torin2 could further 
inhibit proximal tubular growth by blocking both mTORC1 and mTORC2 activity.  Treatment 
with Torin2 showed greater proximal tubular growth inhibition than Rapamycin, which indicates 
both mTORC1 and mTORC2 are involved in proximal tubular development. 
INTRODUCTION 
Organ development is tightly regulated through a highly specific sequence of signaling 
events.  Improperly regulated signal transduction often results in diseases such as cancer and 
polycystic kidney disease (PKD).  PKD is the most common chronic kidney disease in the US.  
The etiology of the disease has been linked to genetic mutations that affect kidney developmental 
signaling pathways [1].  Polycystic kidney disease is characterized by the buildup of fluid filled 
cysts from renal tubule parenchyma cells [1].  Increased cell proliferation in cysts results in an 
increase in cyst size, which compresses nephrons, leading to impaired renal function [1].  There 
is currently no cure for PKD, and the most effective treatments are kidney transplant and dialysis 
[2]. 
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The proteins responsible for kidney development and renal cyst formation are part of the 
mammalian target of Rapamycin (mTOR) complex [3].  The mTOR complex consists of two 
distinct forms, mTORC1 and mTORC2 [4].  In both complexes mTOR is the central 
serine/threonine protein kinase; however, each complex contains different variations of signal 
transduction proteins.  mTORC1 is composed of regulatory-associated protein of mammalian 
target of Rapamycin (raptor) and proline-rich Akt substrate, whereas mTORC2 contains 
Rapamycin-insensitive companion of mTOR (rictor), mammalian stress-activated map kinase-
interacting protein (mSin1), and protein observed with rictor 1 and 2 (protor1/2) [4].  Activation 
of both mTOR complexes occurs in humans suffering from PKD as well as several animal 
models with PKD phenotypes.  The mTORC1 complex activates p70 ribosomal protein S6 
kinase (RPS6K) in cystic epithelium which causes an increase in cell size [3].  The mTORC2 
complex is involved in the development of PKD by causing an increase in Akt phosphorylation 
in cystic epithelial cells which promotes cell growth and proliferation [3].  
 Rapamycin, from which the mTOR pathway was named, is a lipophilic macrolide drug 
isolated from a strain of Streptomyces hygroscopicus that inhibits activation of the mTOR 
complex (Fig. 1) [5,6].  Rapamycin interacts with protein FKBP12 to inhibit mTOR activity, but 
the exact inhibitory mechanism of Rapamycin is not completely understood [4].  This drug has 
been used to reduce renal tubule development and slow cyst growth in several animal models [1].  
Interestingly, Rapamycin inhibits the mTORC1 complex more than the mTORC2 complex [4].  
Since it does not inhibit mTORC2 as well as mTORC1, new drugs that are similar to Rapamycin 
(Rapalogs) are being developed to inhibit both complexes of this pathway. 
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 Torins are an example of these newly developed Rapalogs that have greater inhibitory 
effects on mTOR.  Torins are designed to inhibit mTOR activity by binding directly to the 
mTOR active site, therefore inhibiting mTORC1 and mTORC2 (Fig. 2).  Torin1 was the first 
Torin to be synthesized that had a high selective inhibitory effect on mTOR in vivo [7].  
However, this drug has poor water solubility, a short half-life, and low oral bioavaliabilty [7].  
Scientists have used a medicinal chemistry approach to develop the new drug Torin2 to 
overcome these negative aspects of Torin1 (Fig. 3) [7,8]. 
 The African clawed frog, Xenopus laevis, is a model organism for organogenesis, 
particularly of the kidney.  Xenopus are an ideal model organism for kidney development 
because their kidneys contain a single nephron.  Xenopus embryos are also very efficient for drug 
screenings because the drugs can easily be ingested by the embryos through incorporation into 
the embryo’s growth medium.  Embryogenesis of Xenopus occurs very quickly and is easy to 
observe; fertilized Xenopus eggs develop into swimming tadpoles within 4 days [10].  Kidney 
development in amphibians like Xenopus is unique in that embryos use a sequence of different 
nephric systems for waste disposal and water homeostasis during development [11].  The three 
sequential kidney types that arise from the intermediate mesoderm are the pronephros, 
mesonephros, and the metanephros [12].  The functional pronephros of a Xenopus embryo 
contains three parts: the glomus, the pronephric tubules, and the pronephric duct [12].  The 
glomus is equivalent to the glomerulus of more complex vertebrates, the pronephric tubules 
collect waste filtered by the glomus, and the pronephric duct carries waste to the exterior [12]. 
 The pronephros of Xenopus embryos become morphologically distinguishable around 
developmental stage 22 (Fig. 4) [10].  From stages 22-37 the size of the pronephros remains 
relatively constant in a baseline phase (Fig. 4).  Once the embryos reach stage 38 the pronephros 
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cells begin to rapidly proliferate, and the pronephros undergo expansion; this is known as the 
growth phase (Fig. 4).  The growth phase continues until the embryos reach stage 43 and enter 
the stationary stage.  In the stationary stage, expansion is significantly reduced and terminal 
differentiation occurs (Fig. 4).  Our previous research shows that treating Xenopus embryos with 
Rapamycin reduces their pronephros proximal tubule development by inhibiting mTORC1.  In 
this study, we investigate if Torin2 is able to suppress Xenopus pronephros proximal tubule 
development more effectively by inhibiting both the mTORC1 and mTORC2 complexes. 
MATERIALS AND METHODS 
Embryo Drug Treatment 
Xenopus embryos were obtained using in vitro fertilization and maintained in 0.1x modified 
Barth medium and staged using the method according to Nieuwkoop and Faber [13,14].  
Rapamycin and Torin2 inhibitory drugs were obtained from Tocris Bioscience [9].  The embryos 
were treated by dissolving the drugs in DMSO and adding the drugs into the Barth growth 
medium at stage 34.  Rapamycin was used at a 4.0 µM concentration, and the concentration of 
Torin2 varied. 
Immunohistochemistry and Proliferation Analysis 
For immunohistochemistry on slides embryos were fixed in Dent’s fixative (4:1 
methanol:DMSO), cleared in 70% ethanol, embedded in paraplast, sectioned at 25 µm, dewaxed, 
and stained using the 3G8 monoclonal antibody and either the Phospho-S6 (S235/236) or 
Phospho-AKT (S473) antibodies [11].  The 3G8 antibody was visualized using anti-mouse 
Alexa-555 and the Phospho-S6 (S235/236)/Phospho-AKT (S473) were visualized using Zenon® 
647 (Invitrogen).  For whole mount immunostaining the embryos were incubated overnight with 
the 3G8 monoclonal antibody followed by incubation with a Horseradish peroxidase-coupled 
5 
 
anti-mouse secondary antibody and developed using the ImmPACT DAB kit (Vector 
Laboratories) [11].  The proliferation analysis was performed as previously described [15].  
DAPI was used to label all cell nuclei and the PH3 antibody labels all cells in mitosis. 
RESULTS 
Establishment of an Effective Torin2 Dosage 
The EC50 for Torin2 inhibition of mTOR in cell culture is 0.25 nM [9].  Since we wanted to 
investigate the effects of mTOR inhibition on proximal tubule development in Xenopus in vitro 
an effective dosage concentration needed to be established.  An effective dosage concentration is 
one in which Xenopus proximal tubule development is reduced but normal embryonic 
development is not significantly impaired.  In order to establish an effective Torin2 dosage, 
embryos were treated with varying concentrations of Torin2 from stages 34-42.  As expected, 
Torin2 inhibition of Xenopus proximal tubule development is concentration dependent.  
Treatment with a Torin2 concentration of 0.120 µM reduced the number of proximal tubule cells 
by approximately 50% and decreased the number of dividing cells by 85% (Fig. 5A and 5B).  
When embryos were treated with Torin2 concentrations higher than 0.120 µM the embryos were 
significantly deformed and often disintegrated because of off target effects.  Therefore, we chose 
0.120 µM as the effective dosage to use in further experiments. 
Determination of mTOR Activity 
Treatment with Torin2 clearly reduces the development of proximal tubules in Xenopus 
embryos; however, we had wanted to confirm that the inhibition of mTOR was actually causing 
the reduction of proximal tubule development.  Immunohistochemistry on slides with antibodies 
directed against Phospho-S6 (S235/236) and Phospho-AKT (S473) were used to detect the 
activity of mTORC1 and mTORC2 respectively.  Both mTOR complexes are active in the 
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proximal tubules of untreated embryos, which is indicated by positive red staining for Phospho-
S6 and Phospho-AKT (Fig. 6A and 6A’).  Treatment of Xenopus embryos with Rapamycin 
inhibits mTORC1 (Fig. 6B’); however, mTORC2 remains active in the proximal tubules (Fig. 
6B).  Torin2 is able to inhibit the activity of both mTORC1 and mTORC2, which is indicated by 
the absence of staining for Phospho-S6 and Phospho-Akt respectively (Fig. 6C and 6C’).  These 
results suggest that the inhibition of both mTORC1 and mTORC2 by Torin2 causes the reduction 
of proximal tubule development in Xenopus embryos. 
Reduction of Pronephros Size 
Whole mount immunohistochemistry was used to observe the size of the proximal tubules of the 
pronephros after treatment with Torin2.  At stage 38, the proximal tubules of the Torin2 treated 
embryos are only slightly smaller than the untreated embryos (Fig. 7A and 7A’).  However, at 
stage 42 the proximal tubules of the untreated embryos appear larger than the Torin2 treated 
embryos (Fig. 7B and 7B’).  Embryos treated with Torin2 do not experience the same proximal 
tubule expansion as untreated embryos. 
Torin2 Significantly Inhibits Pronephros Proximal Tubule Development Overtime 
Embryos were treated with Rapamycin and Torin2 from stage 34 to 46 and cell proliferation 
analysis was performed using immunohistochemistry by counting the number of proximal tubule 
cells of each embryo [15].  The proximal tubule growth of the treated embryos over these stages 
was compared to the proximal tubule growth of untreated embryos as a control.  Proximal 
tubules of the embryos treated with Torin2 and Rapamycin only expanded by approximately 100 
cells over this time period (Fig. 8A).  This is a 4-fold decrease in proximal tubule expansion 
compared to untreated embryos.  The number of cells in mitosis is very similar when the 
embryos are treated with either drug (Fig. 8B).  Comparing the percentage of cells that are 
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currently in mitosis is a better statistic to measure development than the number of cells in 
mitosis alone.  Surprisingly, the proximal tubules of embryos treated with Torin2 have a higher 
percentage of cells in mitosis than the embryos treated with Rapamycin, but the percentages at 
each stage are still significantly lower than the untreated embryos (Fig. 8B).   The most 
important statistic in the cell proliferation analysis is the total number of kidney cells at each 
stage since this statistic is a quantitative representation of kidney size.  The number of total cells 
when treated with Torin2 is 20% less than when the embryos are treated with Rapamycin (Fig 
8A).  The more effective expansion inhibition by Torin2 suggests that the mTORC2 complex is 
also involved in proximal tubule expansion since Torin2 is able to inhibit this complex in 
addition to mTORC1, whereas Rapamycin is only able to inhibit the mTORC1 complex.  The 
mTORC2 complex is most likely involved in early proximal tubule cell proliferation and is thus 
why there is a gap in the number of proximal tubule cells at stage 38 between the Rapamycin and 
Torin2 treated embryos (Fig. 8A).  These findings provide evidence for Torin2 being a better 
inhibitor of mTOR in vivo and thus more effective at reducing Xenopus pronephros proximal 
tubule development. 
DISCUSSION 
 mTOR has been shown to have a critical role in normal kidney development and aberrant 
mTOR activity can lead to renal diseases such as Polycystic Kidney Disease.  Treatment with 
Rapamycin has been able to inhibit mTOR activity and reduce kidney proximal tubule 
development in model organisms such as Xenopus.  Although Rapamycin is able to inhibit 
mTOR activity it is only able to inhibit the mTORC1 complex whereas the mTORC2 complex 
remains active (Fig. 6B and 6B’).  This study investigated how the Rapalog Torin2 inhibits 
Xenopus pronephros proximal tubule development compared to Rapamycin.  Treating Xenopus 
embryos with Torin2 inhibits both TORC1 and TORC2 activity in the pronephros proximal 
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tubules (Fig. 6C and 6C’).  We were able to visualize smaller pronephros proximal tubules in 
Torin2 treated embryos through whole mount immunohistochemistry (Fig. 7B and 7B’).  We 
were also able to quantitatively measure the effects of Torin2 on proximal tubule development 
by using the cell proliferation analysis technique established by Romaker et al. [15].  By 
inhibiting both mTOR complexes, Torin2 reduces pronephros proximal tubule expansion more 
effectively than Rapamycin (Fig. 8A).  Although there was a higher percentage of cells in 
mitosis in the embryos treated with Torin2 than Rapamycin, the total number of cells in Torin2 
treated embryos was lower (Fig. 8C and 8B).  These results suggests that Torin2 could 
potentially be a better pharmacological therapeutic for renal developmental diseases such as 
Polycystic Kidney Disease.  
 In order to further investigate the effects of Torin2 on kidney development, it would be 
interesting to reproduce similar experiments using the murine system.  These results would 
provide a better indication of how Torin2 would affect human kidney development since mice 
have similar and more complex kidneys than Xenopus.  It would also be interesting to examine 
the effects of Torin2 treatment on cyst development in mice expressing the PKD phenotype.  
Previous studies have shown that treating PKD mice with Rapamycin is able to reduce kidney 
cyst size and reduce the kidney mass back to wild-type levels [16].  However, Rapamycin 
treatment was not able to reduce the number of cysts in the kidneys [16].  Since Torin2 is able to 
inhibit both mTOR complexes maybe it could potentially reduce the number of cysts in addition 
to cyst size in PKD mice.  Expanding this study to the murine system would provide great insight 
on the potential therapeutic effects of Torin2 for PKD patients.   
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Figure 1. Chemical Structure of Rapamycin.  Rapamycin interacts with the protein FKBP12 
to inhibit the mTORC1 complex.  The exact inhibitory mechanism is not completely understood, 
and Rapamycin is unable to inhibit mTORC2 activity. 
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Figure 2. Schematic Diagram of mTOR Inhibition by Rapamycin and Torin2.  Insulin and 
IgF are two activators of the mTOR pathway in Xenopus. Rapamycin inhibits the mTORC1 
complex by interacting with FKBP12 which inhibits the phosphorylation of S6 thereby 
prohibiting the cell from increasing in size. Torin2 binds directly to the mTOR active site to 
inhibit the mTORC1 and mTORC2 complexes. Inhibition of mTORC2 prevents the 
phosphorylation of Akt which prevents cell growth and proliferation. 
  
11 
 
 
Figure 3. Chemical Structure of Torin2.  Torin2 is a Rapalog that is able to inhibit mTOR by 
binding directly to the active site therefore inhibiting both mTORC1 and mTORC2 activity. 
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Figure 4. Differentiation of Xenopus laevis pronephros. The pronephros proximal tubule 
development can be divided into 3 distinct phases:  stages 22-37: baseline phase, stages 38-42: 
growth phase, stages 43-45: stationary phase. Hpf indicates the hours post fertilization. 
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Figure 5. Effectiveness of Torin2 is Concentration Dependent.  (A) Total number of 
pronephros proximal tubule cells. (B) Number of pronephros proximal tubule cells in mitosis. 
The growth of the proximal tubules was measured after treatment with varying concentrations of 
Torin2.  Torin2 inhibits proximal tubule growth in a concentration dependent manner.  
Treatment with 0.120 μM Torin2 inhibits approximately 50% of tubule growth.  This 
concentration is an effective treatment dose because it inhibits tubule growth without 
significantly impacting normal embryonic development. 
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Figure 6. Rapamycin Inhibits mTORC1 and Torin2 Inhibits mTORC1 and mTORC2.  
Immunohistochemistry on slides with antibodies directed against Phospho-Akt (mTORC2) and  
Phospho-S6 (mTORC1) were used.  Untreated embryos have active mTORC1 and mTORC2 (A 
and A’).  mTORC2 remains active (B) when embryos are treated with Rapamycin however 
mTORC1 is inactivated (B’). Torin2 is able to inhibit both mTORC1 and mTORC2 activity (C 
and C’). 
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Figure 7. Pronephros Size After Torin2 Treatment. Untreated embryos have significant 
proximal tubule expansion from stage 38 to 42 (A and B) while Torin2 prevents this expansion 
(A’ and B’). 
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Figure 8. Cell Proliferation 
Analysis of Pronephros 
Proximal Tubules After Drug 
Treatment.  The proximal 
tubule growth of treated 
embryos from stages 38 to 46 
was compared to the proximal 
tubule growth of untreated 
embryos as a control. Proximal 
tubules of the embryos treated 
with Torin2 only expanded by 
approximately 100 cells over 
this time period (A). This is a 4-
fold decrease in proximal tubule 
expansion compared to 
untreated embryos. The number 
of proximal tubular cells 
dividing over these stages (B) 
and percentage of cells dividing 
(C) were significantly less than 
untreated embryos. Torin2 
reduces proximal tubule 
expansion more effectively than 
Rapamycin (A). The more 
effective expansion inhibition 
by Torin2 suggests that the 
TORC2 complex is also 
involved in proximal tubule 
expansion since Torin2 is able 
to inhibit this complex in 
addition to TORC1, where 
Rapamycin is only able to 
inhibit the TORC1 complex.  
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